Index

Note: Figures and Tables are indicated by italic page numbers, Boxes by emboldened numbers.

abstinence (from alcohol consumption) 132
acamprosate 139
accommodation 8, 239, 241
activities of daily living (ADLs) 8–9, 18
acute confusional state see delirium
acute hospital wards 224
acute stress reaction 103
adherence to medication 150–3
   factors affecting
      doctor-related 152
      drug-related 152
      illness-related 150–1
      patient-related 151–2
   interventions to improve 152, 153
adjustment disorders 103–5, 278–9
   diagnostic criteria 104
   management of 104–5
   advance directives 233
   adverse drug reactions (ADRs) 139–60
      factors affecting 158–9
   advocacy scheme 234
   amnesia 35
   agoraphobia 98–9
   akathisia 189, 190
alcohol, interactions with other drugs 135, 168
alcohol consumption
   definitions 132–3
   guidelines 131–2
   history-taking 10
alcohol dependence 132–3
   detection and screening 133–5
   epidemiology 133
   management of 139–41
   suicide risk 136–7
   alcohol misuse
      consequences 135–9
      dementia and 50–2
      medical complications 135, 136
      social consequences 139
   see also problem drinking
   alcohol withdrawal 140–1
      clinical features 140
      management of 140–1
   alcoholic dementia 51–2, 137
   alcoholic hallucinosis 137
   Alzheimer’s disease (AD) 23, 24, 26, 33–41
      aetiology 36
      clinical features 13, 35
      course and prognosis 34
      depression in 72–3
      diagnostic criteria 33–4
      genetic factors 36
      investigations 27, 39
      neurochemical changes 35
      NICE guidance 40
      pathology 34–5
      possible protective factors 37–9
      risk factors 37, 38
      treatment of 40–1, 198, 199
   amisulpiride 155, 156, 188, 191
   amitriptyline 161, 167, 167, 168, 179
   amnesia 35
   amyloid cascade hypothesis (for Alzheimer’s disease) 36
amyloid plaques 34, 35
antidepressants 31, 67–9, 88, 120, 130, 162–79
anxiety disorders treated with 95, 197
and co-morbid illness 177–8
duration of treatment 162
interactions with other drugs 163–4, 165, 169, 171, 172, 173, 174, 175
onset of action 162
side effects 163, 164, 167–8, 170, 171, 172, 173, 174, 179
see also monoamine oxidase inhibitors;
selective serotonin reuptake inhibitors;
tricyclic antidepressants
antiepileptic drugs 196
interactions with other drugs 165, 178
antihistaminic side effects 160
anti-inflammatory drugs 38, 201
antioxidants 38–9, 201
antiparkinsonian drugs 263
interactions with other drugs 165
side effects 263, 263
antipsychotics 29–30, 87, 130, 186–93, 251–2
atypical drugs 187, 188, 252
derop medication 192–3
dosage 187
indications 187
interactions with other drugs 192
mechanism of action 187
side effects 187–91
typical drugs 187, 188
anxiety
clinical features 13, 14, 92
and depression 93–4
medical conditions causing symptoms 92, 93
anxiety disorders 91–6
epidemiology 92
management of 95–6, 163, 167, 169, 197
and personality disorders 128
see also generalised anxiety disorder
anxiety symptoms, drugs and substances causing 92, 93, 135
anxiolytics 193–6
aphasia 13, 35
appearance 11
apraxia 35
aripiprazole 30, 87, 188
artificial nutrition and hydration (ANH)
risks associated 236
withdrawing or withholding 235–6
assessment of patients 1–22
beginning 2
setting in which made 2–5
association of topics, loosening of 15
Attendance Allowance 240
attorney, power of 233–4, 236–7
augmentation strategies 68–9
awareness 11
bedside testing for cognitive functions 18
behavioural therapy 30, 69, 216
benzodiazepines 31, 75, 87, 95, 148, 193–6, 252, 280
dosage 194
half-lives 193
indications 193–4
interactions with other drugs 195
mode of action 193
overdose 196
side effects 194, 194, 195
tolerance and dependence 195
withdrawal of 195–6
bereavement 66, 73–5
beta-blockers 96, 197
bibliotherapy 69, 214
bipolar affective disorder (BPAD) 81–9
aetiology 82
course and prognosis 89
differential diagnosis 85
epidemiology 81
management of 86–9
mania in 83–4
mixed affective states 84–5
prophylactic pharmacological treatment 88
rapid cycling 85
see also depression; mania
blood tests, alcohol misuse detected by 135
body fat and water, effect on drug distribution 154
Bournewood Case 230
Bristol Activities of Daily Living Scale 18
bulimia nervosa, management of 163, 218
buspirone 95, 196
CAGE questionnaire 133, 134
carbamazepine 31, 86, 185–6
dosage 185
interactions with other drugs 186
side effects 185, 186
cardiac effects, antipsychotics 190
cardiovascular disease 254
and antidepressants 177, 178
anxiety symptoms caused by 93
delirium caused by 245
depression associated with 62–3, 65
Care Programme Approach (CPA) 223
carers, assessment of 20–1
catatonia, ECT treatment of 206
CBT see cognitive behavioural therapy
cerebellum, clinical effects of lesions to 257
cerebral artery occlusion, effects 256
cerebrovascular disease
and antidepressants 177, 178
dementia associated with 41–6
depression associated with 63, 64
Charles Bonnet syndrome 16
chloridiazepoxide 193, 196, 253
chlorpromazine 188, 191
cholesterol-lowering drugs, effects 39
cholinesterase inhibitors 31, 40, 50, 73, 116, 198–200
dosage and preparations 199
mechanism of action 199
side effects 199–200
cimetidine 65, 82, 186, 192, 246, 291, 292
circadian rhythm 145
cumulative mentality 14
citalopram 31, 73, 95, 116, 155, 156, 163, 163, 164, 166, 177, 178, 179
Civil Partnership Act (2004) 239
clinical psychologist 222
clock drawing test 16, 17
clozapine 188, 191, 192
cognitive reserve, effects on Alzheimer's disease 37, 38
community history 10
Community Mental Health Team (CMHT) 2, 224
community psychiatric nurse (CPN) 222
collaboration with 93
coregulation 186
Cortenfant syndrome 273–4
Cushing's syndrome 273–4
day centres 224
day hospitals 224
delirium 244–54
causes 244–6, 245
classification into subtypes 247
clinical features 246, 247
diagnosis 247–9
epidemiology 244
examination and investigations 249–50
factors contributing to mortality 252–3
history taking 249
management of 250–2
medications associated with 245–6, 246, 251
non-pharmacological management of 250, 251
outcomes 252
pathophysiology 246
pharmacological management of 251–2
risk factors 244, 245
delirium tremens 141, 253–4
delusional disorder 118–20
aetiology and risk factors 119
clinical features 119
diagnostic criteria 119–20
epidemiology 119
management of 120
outcomes 120
delusions 15, 62, 83, 111, 280–1
dementia 23–58
  assessment of patient 12, 14, 15
  behavioural and psychological symptoms (BPSD) 28–9
  NICE guidance on management of 31, 32
  non-pharmacological intervention in 30
  pharmacological management of 29–31, 202
  causes 23–5
  classification 26
  depression in 32, 63, 72–3
  diagnostic criteria 23
  differentiation between types 31, 33
  general management of 26, 28
  non–cognitive assessment scales in 20, 21
  and personality changes 124–5
  prevalence 23
  with Lewy bodies (DLB) 24, 26, 26–50
  clinical features 11, 15, 47–9
  diagnosis 47–9
  investigations 27, 49
  management of 49–50, 198
  and Parkinson’s disease dementia 49
  pathology 46–7
  depot medication, antipsychotics 192–3
  depression 59–79
  clinical features 12, 13, 60–2
  cognitive impairment in 61
  and dementia 32, 63, 72–3
  diagnosis 60–1
  electroconvulsive therapy 69–70
  epidemiology 59–60
  features to screen for 13
  outcome 71
  in palliative care 279–80
  pathophysiology 67
  and personality disorders 128
  pharmacological treatment of 67–9, 162–79
  physical illnesses associated 62–3, 63–4
  prevention of 71–2
  psychological therapy for 69, 214–15, 218
  risk factors 62–7
  social intervention 70
  treatment of 67–70
  see also bipolar affective disorder
  detoxification 140–1
  diabetes mellitus
  depression associated with 63, 269
  effect of antipsychotics 191, 269

type I 269
  type II 269–71
  complications 271
  diagnosis 270
  presenting features 269–70
  prevalence 269
  risk factors 269
  treatment of 270
  diabetic ketoacidosis (DKA) 269
diazepam 193–4, 193, 196
Diogenes syndrome 29–30
disinhibition 11, 12, 13, 124
disulfiram 139
DLB see dementia with Lewy bodies
domiciliary visit 2–3
donepezil 161, 199, 199
dopamine transporter studies 48
dopaminergic antagonism, effects 160, 190
dosette box (for medication) 151
dosulepin (dothiepin) 167, 179
Down’s syndrome, risk of Alzheimer’s disease 37
driving, restrictions on 237, 238
drug interactions 161
  antidepressants 163–4, 165, 169, 171, 172, 173, 174, 175
drug side effects 160
  antidepressants 163, 164, 167–8, 170, 171, 172, 173, 174, 179
  drug treatment, principles 149–50
  drugs
  in history-taking 10
  see also medication
DSM-IV diagnostic criteria
  adjustment disorder 104
  agoraphobia 98–9
  bipolar affective disorder 83
delirium 248
dementia 25, 33, 45
  depression 60, 74
  generalised anxiety disorder 94
  personality disorders 125, 126
  post-traumatic stress disorder 101
  schizoaffective disorder 118
  schizophrenia 112–13
  social phobia 100
  DTs see delirium tremens
duloxetine 155
dysarthria 13
dysphasia 13, 35
dysthymia 62

dystonia 189

ECT see electroconvulsive therapy

EEG investigations 19, 27

ECT electroconvulsive therapy (ECT) 69–70, 88, 205–11

adverse effects 207

cautions 208

consent 208

depression treated by 69–70, 206

efficacy 207

indications 69–70, 206

mechanism of action 206

medications affecting 164, 209

and Mental Health Act 208

pre-therapy examination and investigations 208–9

prevention of relapse 211

procedure 209–11

checklist 210

energy dose 210–11

frequency and number of treatments 211

seizure length 210

endocrine disease/disorders 269–74

anxiety symptoms caused by 93

delirium caused by 245

dementia associated with 24

depression associated with 63

Enduring Power of Attorney 236–7

epilepsy 258–60

and antidepressants 178, 178

and antipsychotics 191, 191

differential diagnosis 259–60

investigations 259

new-onset

causes 258

symptoms 259

prevalence 258

treatment of 259

escalolopram 163, 166, 179

evidence-based drug treatment 150

extrapyramidal side effects (EPSs) 54, 60, 87, 116, 160, 187, 188, 189, 190

and drug interactions 165, 183

management strategies for 189, 190

family history 7

family therapy 30, 88, 218

financial issues 239

Mental Capacity Act and 236–7

financial situation of patient 8

‘flight of ideas’ 15

flumazenil (benzodiazepine antagonist) 196, 198, 252

fluoxetine 163, 164, 166, 178, 179, 192

fluvoxamine 163, 166, 179

fMRI (functional magnetic resonance imaging) 57

forensic history 10

frontal lobe, clinical effects of lesions to 257

frontal lobe problems, assessment of patient 12, 14

frontal lobe testing 285–6

temporal-dementia (FTD) 12, 24, 26, 50

clinical features 12, 124

diagnostic guidelines 50, 51

investigations 27, 50

subtypes 50, 52

gabapentin 87

galantamine 199, 199

general hospital wards, assessments made in 4–5

generalised anxiety disorder (GAD) 94–6

clinical features 92, 94

course and prognosis 96

diagnostic criteria 94–5

management of 95–6

genetic factors, Alzheimer’s disease 36, 38

Geriatric Depression Scale (GDS) 13, 283–4

ginkgo biloba 41, 201

grief

abnormal 74–5

management of 75

normal reaction 73, 74

group therapy 139

Hachinski ischaemic rating system 45, 46

hallucinations 16, 48, 62, 83, 111, 137, 280–1

haloperidol 30, 155, 156, 165, 187, 188, 191, 251, 254

healthcare charges 240

heating costs, assistance with 240

hepatic drug metabolism 155

hepatically impaired patients, prescribing for 155, 195

history taking 5–10, 249

HIV 266

psychosis 266
INDEX

HIV-associated dementia (HAD) 24, 26, 54, 266
intestinal absorption (of drugs) 154
home modifications, assistance with 240
investigations 18, 19, 27, 56–7
homeostatic mechanisms, and drug effects 157–8
isocarboxazid 170, 170, 171, 172, 179
Korsakoff psychosis 138, 275
hospital wards 224
Huntington's disease 24, 26, 27, 52–4
Korenblat psychosis 138, 275
hyperosmolar non-ketoacidosis (HONK) 270
hyperthyroidism 272–3
lithium 86, 155, 156
hypothyroidism 271–2
lamotrigine 87, 155, 156
ICD-10 diagnostic criteria
Lasting Power of Attorney (LPA) 233–4
adjustment disorder 104
legal issues 225–38
agoraphobia 98
legislation
bipolar affective disorder 83
Civil Partnership Act (2004) 239
delirium 248
Mental Capacity Act (2005) 230–7
delusional disorder 119–20
Mental Health Act (1983) 225–30
dementia 25, 33, 44
Patients in the Community Act (1995) 228
depression 60
Lewy body disorders 46–7
generalised anxiety disorder 94
see also dementia with Lewy bodies (DLB);
mania 84
Parkinson's disease; Parkinson's disease
obsessive compulsive disorder 106
with dementia (PDD)
panic disorder 96–7
lewy body disorders 46–7
personality disorders 125
medication
post-traumatic stress disorder 101
adherence 150–3
schizophrenia 111–12
medication
social phobia 99–100
medication
imipramine 167, 168, 178, 179
interpersonal psychotherapy (IPT) 30, 69, 70,
inpatient psychiatric nurse 222
129, 218–19
insight, assessment of 17
insomnia 143–8
clinical features 11, 12, 13, 14, 15, 83–4
medication
adherence 150–3
diagnostic criteria 84
episodic memory loss 27
see also bipolar affective disorder
depression caused by 65
depression treated by 67–9
drug interactions 40
in history-taking 9
non-pharmacological management of 147
interactions with alcohol 135
pharmacological management of 147–8,
see also drugs; pharmacological therapy
197

lobe function testing 18, 256, 285–7
lofepramine 156, 167, 167, 168, 178, 179
lorazepam 31, 87, 155, 156, 193, 194, 196
Lund–Manchester diagnosis guidelines 50, 101

mania 83–4
clinical features 11, 12, 13, 14, 15, 83–4
see also bipolar affective disorder

consequences 145
non-pharmacological management of 147
INDEX

memantine 31, 40, 200–1
memory clinic 18–20
Mental Capacity Act 2005 (MCA) 230–7
    advance directives 233
    assessment of capacity 231–2
    consent to treatment 235, 250
    criteria for intrusive research 234
    financial issues 236–7
    guiding principles 231, 231
    independent advocacy scheme 234
Mental Health Act 1983 (England and Wales) 225–30
    appeals 225, 226, 229
    compulsory admission provisions 225, 226–7
    and ECT 208
    Section 117 aftercare 229–30
    sections listed 227–9
Mental Health Review Tribunal (MHRT) 225, 229
Mental State Examination (MSE) 10–17
    appearance 11
    awareness 11
    behaviour 12
    cognition 16, 17–18
    insight 17
    mood 13–14
    perception 16
    speech 12–13
    thought content 15–16
    thought form 14–15
    see also Mini Mental State Examination (MMSE)
metabolic imbalance, delirium caused by 245
mild cognitive impairment (MCI) 55–6
Mini Mental State Examination (MMSE) 16, 17, 248, 289–90
mirtazapine 68, 102, 174–5
    dosage 174
    interactions with other drugs 174
    side effects 174, 174, 179
    stopping 175
    switching to/from another antidepressant 166, 169, 172, 175
mixed Alzheimer's and vascular dementia 43
MMSE see Mini Mental State Examination
moclobemide 68, 170, 171, 172, 178, 179
    monoamine oxidase A inhibitor see moclobemide
    monoamine oxidase B inhibitor see selegiline
monoamine oxidase inhibitors (MAOIs) 169–72
    cautions 169
    contraindications 171
    dosage 170
    food interactions 171, 171
    interactions with other drugs 163–4, 165, 169, 171, 172, 173, 174
    mode of action 170
    side effects 170, 171, 179
    stopping 172
    switching to/from another antidepressant 166, 169, 172, 172
mood, assessment of 13–14
mood disorders 59–89
    in palliative care 279–80
    see also bipolar affective disorder; depression
    mood stabilisers 31, 86–7, 130, 183–6
    mortality rates 117–18
    MRI/CT investigations 19, 27, 56
    multidisciplinary working 222–3
    multi-infarct dementia 43
naltrexone 130, 139
neoplastic disease 276–7
neurofibrallary tangles 34, 35
neuroimaging 19
    for dementia 27, 56–7
    for schizophrenia 116
neuroleptic malignant syndrome (NMS) 191, 246
neuroleptic sensitivity 48
neurological disease/disorders 258–66
    anxiety symptoms caused by 93
    confused with epilepsy 260
    delirium caused by 245
    neuropsychiatric testing 18–20
NICE guidelines/recommendations
    Alzheimer's disease 40, 57, 199, 200
    dementia 31, 32, 57
    depression 67
    ECT 206
    hypnotics 198
    obsessive compulsive disorder 107
    post-traumatic stress disorder 103
NIMH criteria, depression in Alzheimer's disease 72–3
NINCDS-ADRDA criteria, probable
    Alzheimer's disease 34
NINCDS-AIREN criteria, probable vascular dementia 45
INDEX

nitrazepam 193, 196, 198
non-cognitive assessment scales in dementia 20, 21
non-fluent progressive aphasia 52
non-REM sleep 143, 144
non-steroidal anti-inflammatory drugs (NSAIDs) 38, 201
interactions with other drugs 161, 165
normal pressure hydrocephalus (NPH) 264–5
nortryptiline 167, 168, 177, 178, 179
nursing home 241
costs 241
nutritional deficit 274–6
obsessions 15, 105
obsessive compulsive disorder (OCD) 105–7
clinical features 105
co-morbidity with other disorders 106
diagnostic criteria 106
management of 106–7, 163, 167, 169
occupational therapist (OT) 222
olanzapine 30, 87, 89, 116, 156, 187, 188, 191
outpatient clinics 3–4
overvalued ideas 16
oxazepam 155, 193, 196, 253
pain management 277–8
palliative care 277–81
adjustment disorders 278–9
hallucinations and delusions 280–1
mood disorders 279–80
WHO definition 277
panic attacks 14, 96, 97
panic disorder 96–7
paraneoplastic limbic encephalitis (PLE) 276
parietal lobe, clinical effects of lesions to 257
parietal lobe testing 286–7
Parkinson’s disease 260–4
aetiology 262
and antidepressants 177–8, 178
clinical features 261
co-morbidity with other disorders 24, 49, 63, 106
epidemiology 262
management of 170, 192
non-motor symptoms 261
psychiatric symptoms 261
treatment of 170, 263–4
with dementia (PDD) 24, 49, 261
Parkinsonism
conditions causing 262
as extrapyramidal side effect 189
management of 189
paroxetine 155, 163, 164, 178, 179
past medical history 8–9
past psychiatric history 7–8
Patients in the Community Act (1995) 228
pensions 239
perception, assessment of 16
perseveration 14
personality 123–4
and ageing 124–5
describing 123–4
personality changes
and dementia 124–5
and medical illness 125
personality disorders 16, 65, 123–30
changes with age 127–8
classification 125
dementia in patients with 125
and depression 128
diagnosis in later life 127
diagnostic criteria 125, 126
epidemiology 125, 127
management of 129–30
and psychotic disorders 129
relevance in old age 128
PET (positron emission tomography)
investigations 19, 27, 57
pharmacodynamics, age-related changes 157–8, 159
pharmacokinetics, age-related changes 153–6, 158
pharmacological therapy 149–203
alcohol dependence 139
Alzheimer’s disease 40–1
anxiety disorder 95–6
bipolar affective disorder 86–8, 89
delirium 251–2
delusional disorder 120
dementia 29–31
depression 67–9
insomnia 147–8, 197
obsessive compulsive disorder 107
personality disorders 130
schizophrenia 116
phenelzine 170, 171, 172, 179
phenothiazines 155, 188, 192
phobic disorders 97–101
management of 100–1
see also agoraphobia; social phobia
physical examination 18
physical illnesses 243–81
and depression 62–3, 63–4
and personality changes 125
physician-assisted suicide 281
Pick’s disease 52
pimozide 120
plasma protein binding of drugs 154–5
polypharmacy 159
post-stroke dementia 42
post-traumatic stress disorder (PTSD) 101–3
diagnostic criteria 101, 102
management of 102–3, 163, 167
pregabalin 96, 196–7
premorbid personality 10
prescription charges 240
prion disease 54
problem drinking 132
prevalence 133
screening for 133, 134
see also alcohol misuse
prochlorperazine 161
progressive supranuclear palsy 24, 26, 52
psychiatric history 5–10
psychiatric nurses 222
psychiatric wards, assessments made in 4
psychoanalytic/psychodynamic psychotherapy 129, 217–18
psychogenic disorders 260
psychological therapies 213–19
for bipolar affective disorder 88
for dementia 28, 30
for depression 69, 70
for obsessive compulsive disorder 107
for personality disorders 129
for schizophrenia 117
psychometric tests 20
psychopharmacology 149–203
psychosis, assessment of patient 15, 16
psychotic illness 109–21
differential diagnosis 114
and personality disorders 129
see also delusional disorder; schizophrenia
quetiapine 30, 87, 89, 188, 191, 252
reality orientation therapy 30, 219
reboxetine 169, 172, 175
receptor changes, age-related 157
referrals 2
REM sleep 143, 144
behaviour disorder 48
reminiscence therapy 30, 219
renal drug elimination 156
renal impairment, drug-caused 183, 195
renally impaired patients, prescribing for 156
research trials 234
residential home 241
costs 241
respiratory diseases
anxiety symptoms caused by 93
risks associated with benzodiazepines 195
rheumatological disease 267–8
risk areas 6
risperidone 30, 87, 89, 116, 187, 188, 191, 192, 252
rivastigmine 199, 199, 200
Royal College of Psychiatrists, indications for
ECT 206
St John’s Wort 175
same-sex couples, support for 239
schizoaffective disorder 118
schizophrenia 109–18
aetiology and risk factors 110–11
clinical features 12, 111
co-morbidity with other disorders 116
cognitive deficits 115
definitions 109, 110
and dementia 115
diagnostic criteria 111–13
early-onset, changes with ageing 113, 114
epidemiology 110
late-onset 113–14, 114
management of 116–17, 192
neuroimaging for 116
outcomes 117–18
seizures, and antipsychotics 191
selective serotonin reuptake inhibitors (SSRIs) 50, 67, 97, 101, 102, 107, 130, 162–6, 177, 178, 178, 280
dosage 163
half-lives 166
interactions with other drugs 161, 163–4, 192
mode of action 162–3
side effects 163, 164, 179
switching to/from another antidepressant 166, 169, 172
withdrawal symptoms 164, 165, 166
selegiline 161, 165, 170, 177, 178, 179, 263
semantic dementia 13, 52
serotoneric side effects 160
serotonin syndrome 161, 164, 165, 169, 175, 176, 246
sertraline 156, 163, 177, 178, 179
services, provision of 222–5
sheltered accommodation 241
Short Michigan Alcohol Screening Test - Geriatric (SMART-G) 133, 134
side effects, antidepressants 163, 164, 167–8, 170, 171, 172, 173, 174, 179
sleep architecture 143–4
changes with age 144
sleep diary 146
sleep disorders, confused with epilepsy 260
sleep hygiene measures 147, 148
social history 8–9
social interventions 9, 28, 70, 116–17
social phobia 99–100
social worker 222
somatic syndrome (in depression) 60, 61
SPECT (single photon emission tomography) investigations 19, 27, 48, 56
speech ability 12–13
SSRIs see selective serotonin reuptake inhibitors
stress, reactions to 101–5
stroke 254–7
and antidepressants 177, 178
complications 256
presentation of 255–6
risk factors 254–5
treatment of 256–7
subcortical dementia 26
subcortical ischaemic vascular dementia 43
subdural haematoma (SDH) 258
substance withdrawal, delirium caused by 245
suicidality, terminally ill patients 280
suicide 71, 76–8
and alcohol dependence 136–7
assisted 281
epidemiology 76
prevention of 78
risk factors 77, 77–8
sulphpride 54, 155, 156, 188, 191
systemic lupus erythematosus (SLE) 267–8
tardive dyskinesia 189, 190
telephone costs, assistance with 240
temazepam 155, 193, 196, 198
temporary arteritis 267
temporary lobe, clinical effects of lesions to 257
temporary lobe testing 287
terminal illness, management of 277–81
testamentary capacity 237
tetrahydrobiopterin 54, 190
thiamine deficiency 24, 50, 138, 274–5
thought content 15–16
thought form 14–15
thyroid hormone deficiency 271–2
topiramate 87
transient ischaemic attack (TIA) 254
transport, assistance with 240
tranlycyclpromine 170, 170, 171, 172, 179
trazodone 31, 68, 172, 177, 178, 178, 197
side effects 172, 179
switching to/from another antidepressant 169, 172
tricyclic antidepressants (TCA) 67, 68, 102, 166–9
cautions and contraindications 168, 177, 178, 178
dosage 167
interactions with other drugs 169, 192
mode of action 167
side effects 167–8, 168, 179, 280
stopping 169
switching to/from another antidepressant 166, 169, 172
toxicity 168
trimipramine 167, 179
tyramine-rich foods, adverse reactions 169, 171
valproate 31, 86, 155, 183, 184–5
dosage 184
interactions with other drugs 185
side effects 184, 185
variant Creutzfeldt–Jakob disease (vCJD) 24, 27, 54, 55
vascular dementia 24, 26, 41–6
aetiology 42
causes 41–2
clinical features 43–4
course and prognosis 46
diagnostic criteria 44–5
investigations 19, 27, 46
management of 46, 198
pathology 42–3
types 41–2
vascular depression 64–5
vascular disease 254–8
confused with epilepsy 260

effect on Alzheimer’s disease 37, 38
investigations 19
venlafaxine 68, 95, 173–4, 177, 178
interactions with other drugs 171, 173
side effects 173, 179
stopping 173
switching to/from another antidepressant 166, 169, 172, 174
visual hallucinations 16, 48
vitamin B12 deficiency 275–6
vitamin deficiency
dementia associated with 24, 50, 276
depression associated with 63, 276
vitamin E 41, 201
weight gain, drug-caused 179, 188, 190–1
welfare benefits 240–1
Wernicke encephalopathy 138, 275
Wernicke–Korsakoff syndrome 24, 50, 51, 138
wills 237
Wilson’s disease 24, 26

“Z” drugs see zaleplon; zolpidem; zopiclone
zaleplon 148, 198
zolpidem 148, 198
zopiclone 148, 155, 156, 198